In our previous study to overcome the resistance of EGFR-TK inhibitors, 1-oxo-1,2,3,4-tetrahydropyrazino[1,2-a]indole-3-carboxamide analogs were designed, synthesized, and evaluated against the MCF-7 cell line as a breast cancer subtype with hormone receptors and the MBA-MD-468 cell line as EGFR-overexpressing TNBC. This evidence concerns the gene NR4A1 and breast carcinoma.